

340B's Uphill Legal Battle for Hospital Associations

As discussed in the December 2017 *Health Capital Topics* article entitled, “*Massive Cuts Made to 340B Prescription Drug Discount Program*,” the 2018 Hospital Outpatient Prospective Payment System (OPPS) final rule cut Medicare Part B and state Medicaid payments under the 340B Drug Discount Program (340B Program) by an estimated \$1.6 billion.¹ These cuts faced fierce opposition prior to their January 2018 implementation, and several hospital groups, including the American Hospital Association (AHA), Association of American Medical Colleges (AAMC), and America's Essential Hospitals (AEH), filed legal action to block these cuts from taking effect.² On July 17, 2018, the D.C. Circuit Court of Appeals, affirming the decision of the District Court, dismissed the lawsuit for failure to satisfy the presentment requirement for judicial review;³ the hospital group plaintiffs plan to refile the suit in hopes of obtaining a binding decision by the end of 2018.⁴

The 340B Program was created by Congress in 1992 in an effort to provide the vulnerable and uninsured with access to prescription medications at safety-net facilities, i.e., those serving a high number of the vulnerable or uninsured patient population (termed “covered entities”).⁵ In 1994, the Health Resources and Services Administration (HRSA) released guidance allowing the off-campus outpatient sites of 340B hospitals to be included as covered entities, and in 1996, HRSA released guidance that allowed covered entities without an on-site pharmacy to contract with one off-site pharmacy.⁶ In 2010, HRSA released guidance allowing all covered entities to have an unlimited number of contract pharmacies, and with the passage of the Patient Protection and Affordable Care Act (ACA) that same year, 340B eligibility was extended to: (1) critical access hospitals; (2) sole community hospitals; (3) rural referral centers; and, (4) cancer centers.⁷ When enacted, the 340B Program required pharmaceutical manufacturers to enter into *pharmaceutical pricing agreements* (PPA) with the Department of Health and Human Services (HHS) to ensure discounts for hospitals and clinics serving the most vulnerable patient populations.⁸ In 2016, the median amount of uncompensated care provided by hospitals participating in the 340B Program was higher than their non-340B counterparts; between 2011 and 2016, the number of hospitals participating in the 340B Program increased by more than 60%, largely due to the ACA broadening program eligibility.⁹

The ACA eligibility expansion led to the 2014 statement by Kathleen Sebelius (then Secretary of HHS), during testimony before the Senate Finance Committee, that the 340B Program “has expanded beyond its bounds” (i.e., the number of 340B Program participants had increased to an unsustainable amount).¹⁰ Further, according to the Government Accountability Office (GAO), the number of unique contract pharmacies in 2010 was 1,300, but by 2017, that number had jumped up to 18,700, a more than 1,300% increase.¹¹ The HHS Office of Inspector General (OIG) believes that these “contract pharmacy arrangements complicate efforts to prevent diversion and duplicate discounts,” both of which would (allegedly) be in violation of 340B Program requirements.¹² Hospital lobbyists have argued that the 340B Program is vital to safety-net providers serving low-income populations, while drugmakers have differing opinions on the program’s scope and reach.¹³

In July 2017, the Centers for Medicare and Medicaid (CMS) proposed changes to the 2018 OPPS that significantly impacted the 340B Program.¹⁴ As discussed in the August 2018 *Health Capital Topics* article, “*CMS Continued Payment System Overhaul: OPPS Proposed Rule*,” the finalized 2018 OPPS covered outpatient drugs and biologicals at a rate of the drug’s average sales price (ASP) minus 22.5%, compared to the original payment system rate, i.e., ASP plus 4.3%; this resulted in both large payment reductions to the 340B Program and significantly higher drug expenditures for those hospitals participating in the program.¹⁵

The 2018 OPPS proposed rule was finalized on November 13, 2017, and on the same day, AHA, AAMC, and AEH filed the aforementioned lawsuit against HHS in the D.C. District Court, in an effort to prevent the 340B payment cuts from taking effect.¹⁶ These hospital associations argued that the HHS Secretary lacked authority to establish an average-price metric, and that a 30% payment reduction cannot qualify as a mere “payment adjustment.”¹⁷ HHS stated that these 340B payment reductions were justified based on developments in the market and the program’s overexpansion;¹⁸ ultimately, the District Court dismissed the case for lack of subject-matter jurisdiction, specifically for the associations’ failure to present claims for reimbursement to the HHS Secretary, as required for judicial review under Medicare.¹⁹ The hospital associations appealed the case to the D.C. Circuit Court

of Appeals, and on May 4, 2018, the AHA, alongside 34 state and regional hospital associations, asserted during oral arguments that they satisfied the presentment requirement by filing comments opposing the new OPSS rule during the informal rulemaking process.²⁰ But on July 17, 2018, the Court of Appeals affirmed the District Court’s ruling and dismissed the case on the same subject-matter jurisdiction grounds.²¹

CMS Administrator, Seema Verma, stated, “*The court’s ruling is a big win for patients, who this year alone are expected to save \$320 million in out-of-pocket expenses for medicines in their doctors’ offices...[t]his policy is providing relief every day from the rising costs of drugs, a top priority for President Trump.*”²² The hospital associations released a statement shortly after the ruling expressing their disappointment over the courts “*once again fail[ing] to rule on the merits of [the] case.*”²³ The associations also stated that they plan to continue their fight to reverse these “*unwarranted*” 340B payment cuts and protect access for patients; they expect to refile “*promptly*” in district court.²⁴

The straining effects of the 340B payment cuts have been further exacerbated in the 2019 OPSS proposed rule, by extending these cuts to drugs provided in non-excepted off-campus *hospital outpatient provider-based departments* (HOPDs) (i.e., a hospital-affiliated provider-based facility located off of the hospital’s main campus).²⁵ On July 25, 2018, AHA released a condemnatory statement in regards to the proposal to expand the 340B cuts to a significant number of additional HOPDs and life-saving drugs. AHA stated,

“...like the previous cuts...[this proposal] requires no federal contributions...but instead relies on discounts required of drug companies, [which] exceed[s] CMS’s statutory authority and remain subject to legal challenge.”²⁶

Despite CMS cuts to the program through OPSS rulemaking, Congress is seeking information on how to improve upon the 340B Program. On August 1, 2018, the Energy and Commerce Committee of the U.S. House of Representatives sent letters to nine 340B contract pharmacy participants, seeking information related to their 340B Program participation.²⁷ These letters were sent in response to a June 2018 GAO report that found weaknesses in contract pharmacies’ compliance with 340B Program requirements.²⁸

Because prescription drug affordability is such a prevalent and predominant problem in the U.S. healthcare industry, it is debatable as to whether making significant cuts to the 340B Program is the most effective way to address it. The AHA asserts that the 340B Program represents a very small portion of national drug expenditures, and 340B Health states that the 340B presence in the overall drug market “*cannot plausibly be causing manufacturers to increase drug prices.*”²⁹ According to HRSA data, in 2016, the 340B Program accounted for only 3.6% of the total U.S. drug market.³⁰ Time will tell if the current administration’s efforts to lower drug prices will actually increase access and affordability for the patient, or if drug manufacturers will remain the sole market beneficiaries in the pharmaceutical industry.

1 “Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs” 42 C.F.R. § 414, 416, 419 (November 13, 2017); “CMS Issues Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System and Quality Reporting Programs Changes for 2018 (CMS-1678-FC)” CMS, Press Release, November 1, 2017, <https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2017-Fact-Sheet-items/2017-11-01.html> (Accessed 7/18/18).

2 “D.C. Circuit Rejects Hospital’s Challenge to 340B Drug Payment Cuts” AHLA, July 20, 2018, <https://www.healthlawyers.org/News/Health%20Lawyers%20Weekly/Pages/2018/July%202018/July%2020%202018/D-C--Circuit-Rejects-Hospitals-Challenge-to-340B-Drug-Payment-Cuts.aspx> (Accessed 7/23/18).

3 *Ibid.* The *presentment requirement* is one of the two preconditions required by 42 U.S.C. § 405(g) for obtaining judicial review of covered Medicare claims – the plaintiff must have “*presented*” the claim to the Secretary because without presentment “*there can be no ‘decision’ of any type*” – also required by § 405(g). See “American Hospital Association, et al. v. Alex Michael Azar, HHS” Case No. 1:17-cv-02447 (D.C. July 17, 2018). Appeal from the United States District Court for the District of Columbia, p. 6.

4 “340B showdown: Big pharma, hospitals squaring off in lobbying fight” By Susannah Luthi, *Modern Healthcare*, July 21, 2018, <http://www.modernhealthcare.com/article/20180721/NEWS/180729987> (Accessed 7/23/18).

5 “Legislative and Regulatory History of the Evolution of 340B program” PhRMA, February 2017, available at: <https://www.phrma.org/fact-sheet/legislative-and-regulatory-history-of-the-evolution-of-340b-program> (Accessed 8/8/18).

6 *Ibid.*

7 *Ibid.*

8 “Overview of the 340B Drug Pricing Program” 340B Health, 2018, <https://www.340bhealth.org/340b-resources/340b-program/overview/> (Accessed 7/19/18).

9 “GAO Report Compares 340B Hospitals with Non 340B Hospitals” AHLA, July 20, 2018, <https://www.healthlawyers.org/News/Health%20Lawyers%20Weekly/Pages/2018/July%202018/July%2020%202018/GAO-Report-Compares-340B-Hospitals-with-Non-340B-Hospitals.aspx> (Accessed 7/23/18).

10 PhRMA, February 2017.

11 “E&C Leaders Press 340B Contract Pharmacies for Information” Energy & Commerce Committee, Press Release, <https://energycommerce.house.gov/news/press-release/ec-leaders-press-340b-contract-pharmacies-for-information/> (Accessed 8/7/18).

12 *Ibid.*

13 AHLA, July 20, 2018.

14 PhRMA, February 2017.

15 “Medicare’s Hospital Outpatient Prospective Payment System Proposed Rule: Big Changes For 2019” By Billy Wynne, *Health Affairs*, July 27, 2018, <https://www.healthaffairs.org/doi/10.1377/hlbgol20180727.105372/full/> (Accessed 8/1/18); For more information on these 340B cuts, see the December 2017 *Health Capital Topics* article entitled “Massive Cuts Made to 340B Prescription Drug Discount Program” *Health Capital Topics*, Vol. 10, No. 12 (December 2017), https://www.healthcapital.com/hcc/newsletter/12_17/HTML/340B/10.12_formatted_hc_topics_340b_12.22.17.php (Accessed 8/1/18). Payment was determined by ASP plus 6%, but budget sequester effective April 1, 2013 through 2025 reduced payments providers receive by 1.6%, resulting in a net payment equivalent to ASP plus 4.3%: “Chapter 2: Medicare Part B drug payment policy issues” MedPAC, June 2017, <http://www.medpac.gov/docs/default->

-
- source/reports/jun17_ch2.pdf?sfvrsn=0, p. 67, n. 4 (Accessed 8/02/18).
- 16 “Hospital case against 340B drug payment cuts heads to U.S. Court of Appeals” Revenue Cycle Advisor, April 2, 2018, <https://revenuecycleadvisor.com/news-analysis/hospital-case-against-340b-drug-payment-cuts-heads-us-court-appeals> (Accessed 8/9/18); Case No. 1:17-cv-02447, D.C. July 17, 2018, p. 4.
- 17 *Ibid.*
- 18 Revenue Cycle Advisor, April 2, 2018.
- 19 Case No. 1:17-cv-02447, D.C. July 17, 2018, p. 4.
- 20 Case No. 1:17-cv-02447, D.C. July 17, 2018, p. 7.
- 21 Case No. 1:17-cv-02447, D.C. July 17, 2018, p. 11.
- 22 AHLA, July 20, 2018.
- 23 “Hospitals Vow to Refile After 340B Suit Rejected on Appeal” By Steven Porter, Health Leaders, July 17, 2018, <https://www.healthleadersmedia.com/finance/hospitals-vow-refile-after-340b-suit-rejected-appeal> (Accessed 8/9/18).
- 24 Porter, July 17, 2018; “Hospital Groups Continue Fight to Reverse Cuts for 340B Hospitals” AHA, July 17, 2018, <https://www.aha.org/press-releases/2018-07-17-hospital-groups-continue-fight-reverse-cuts-340b-hospitals> (Accessed 8/9/18).
- 25 For more information, see “CMS Continued Payment System Overhaul: OPPS Proposed Rule” Health Capital Consultants, Vol. 11, Issue 8 (August 2018). “CMS Targets Off-Campus Provider-Based Departments in 2019 OPPS Proposed Rule” Polsinelli, July 2018, <https://sites-polsinelli.vuturvevx.com/33/977/july-2018/upd0718eri.asp?sid=16fc9a05-9e5f-48f3-832d-6605cbc599aa> (Accessed 7/31/18). “Non-excepted” off-campus HOPDs are HOPDs that are not allowed to bill under OPPS in accordance with the Bipartisan Budget Act of 2015 (BBA).
- 26 “Statement on Proposed CY 2019 Outpatient OPPS Rule” By Tom Nickels, AHA, July 25, 2018, <https://www.aha.org/press-releases/2018-07-25-statement-proposed-cy-2019-outpatient-oppo-rule> (Accessed 8/9/18).
- 27 Energy & Commerce Committee, August 1, 2018.
- 28 Energy & Commerce Committee, August 1, 2018.
- 29 “Statement of the American Hospital Association for the Committee on Health, Education, Labor and Pensions of the United States Senate: ‘Effective Administration of the 340B Drug Pricing Program’” AHA, June 19, 2018, <https://www.aha.org/system/files/2018-06/180619-aha-statement-help-hearing-340B.pdf> (Accessed 8/9/18); “RE: RIN 0991-ZA49: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs” 340B Health, Letter to The Honorable Alex Azar (July 16, 2018), https://www.340bhealth.org/files/340B_Health_RFI_Comments_Final.pdf (Accessed 8/13/18), p. 4.
- 30 AHA, June 19, 2018.



(800)FYI - VALU

*Providing Solutions
in the Era of
Healthcare Reform*

Founded in 1993, HCC is a nationally recognized healthcare economic financial consulting firm

- [HCC Home](#)
- [Firm Profile](#)
- [HCC Services](#)
- [HCC Experts](#)
- [Clients & Projects](#)
- [HCC News](#)
- [Upcoming Events](#)
- [Contact Us](#)
- [Email Us](#)

HCC Services

- [Valuation Consulting](#)
- [Commercial Reasonableness Opinions](#)
- [Commercial Payer Reimbursement Benchmarking](#)
- [Litigation Support & Expert Witness](#)
- [Financial Feasibility Analysis & Modeling](#)
- [Intermediary Services](#)
- [Certificate of Need](#)
- [ACO Value Metrics & Capital Formation](#)
- [Strategic Consulting](#)
- [Industry Research Services](#)



Todd A. Zigrang, MBA, MHA, ASA, FACHE, is the President of **HEALTH CAPITAL CONSULTANTS (HCC)**, where he focuses on the areas of valuation and financial analysis for hospitals, physician practices, and other healthcare enterprises. Mr. Zigrang has over 20 years of experience providing valuation, financial, transaction and strategic advisory services nationwide in over 1,000 transactions and joint ventures. Mr. Zigrang is also considered an expert in the field of healthcare compensation for physicians, executives and other professionals.

Mr. Zigrang is the co-author of "[The Adviser's Guide to Healthcare – 2nd Edition](#)" [2015 – AICPA], numerous chapters in legal treatises and anthologies, and peer-reviewed and industry articles such as: *The Accountant's Business Manual* (AICPA); *Valuing Professional Practices and Licenses* (Aspen Publishers); *Valuation Strategies*; *Business Appraisal Practice*; and, *NACVA QuickRead*. In addition to his contributions as an author, Mr. Zigrang has served as faculty before professional and trade associations such as the American Society of Appraisers (ASA); American Health Lawyers Associate (AHLA); the American Bar Association (ABA); the National Association of Certified Valuators and Analysts (NACVA); Physician Hospitals of America (PHA); the Institute of Business Appraisers (IBA); the Healthcare Financial Management Association (HFMA); and, the CPA Leadership Institute.

Mr. Zigrang holds a Master of Science in Health Administration (MHA) and a Master of Business Administration (MBA) from the University of Missouri at Columbia. He is a Fellow of the American College of Healthcare Executives (FACHE) and holds the Accredited Senior Appraiser (ASA) designation from the American Society of Appraisers, where he has served as President of the St. Louis Chapter, and is current Chair of the ASA Healthcare Special Interest Group (HSIG).



John R. Chwarzinski, MSF, MAE, is Senior Vice President of **HEALTH CAPITAL CONSULTANTS (HCC)**. Mr. Chwarzinski's areas of expertise include advanced statistical analysis, econometric modeling, as well as, economic and financial analysis. Mr. Chwarzinski is the co-author of peer-reviewed and industry articles published in *Business Valuation Review* and *NACVA QuickRead*, and he has spoken before the Virginia Medical Group Management Association (VMGMA) and the Midwest Accountable Care Organization Expo. Mr. Chwarzinski holds a Master's Degree in Economics from the University of Missouri – St. Louis, as well as, a Master's Degree in Finance from the John M. Olin School of Business at Washington University in St. Louis. He is a member of the St. Louis Chapter of the American Society of Appraisers, as well as a candidate for the Accredited Senior Appraiser designation from the American Society of Appraisers.



Jessica L. Bailey-Wheaton, Esq., is Vice President and General Counsel of **HEALTH CAPITAL CONSULTANTS (HCC)**, where she conducts project management and consulting services related to the impact of both federal and state regulations on healthcare exempt organization transactions and provides research services necessary to support certified opinions of value related to the Fair Market Value and Commercial Reasonableness of transactions related to healthcare enterprises, assets, and services. Ms. Bailey-Wheaton is a member of the Missouri and Illinois Bars and holds a J.D., with a concentration in Health Law, from Saint Louis University School of Law, where she served as Fall Managing Editor for the *Journal of Health Law & Policy*.



Daniel J. Chen, MSF, is a Senior Financial Analyst at **HEALTH CAPITAL CONSULTANTS (HCC)**, where he develops fair market value and commercial reasonableness opinions related to healthcare enterprises, assets, and services. In addition, Mr. Chen prepares, reviews and analyzes forecasted and pro forma financial statements to determine the most probable future net economic benefit related to healthcare enterprises, assets, and services, and applies utilization demand and reimbursement trends to project professional medical revenue streams, as well as ancillary services and technical component (ASTC) revenue streams. Mr. Chen has a Master of Science in Finance from Washington University St. Louis.